Wells Fargo Downgrades Cabaletta Bio(CABA.US) to Hold Rating, Cuts Target Price to $6

Moomoo NewsDec 20, 2024 13:31 ET · Ratings

Evercore Initiates Cabaletta Bio(CABA.US) With Hold Rating, Announces Target Price $6

Moomoo NewsDec 20, 2024 13:31 ET · Ratings

Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)

TipRanksDec 20, 2024 12:20 ET · Ratings

BofA Securities Cuts Price Target on Cabaletta Bio to $29 From $31, Keeps Neutral Rating

MT NewswiresDec 20, 2024 10:02 ET · Ratings

Cabaletta Bio Cut to In-Line From Outperform by Evercore ISI Group

Dow JonesDec 20, 2024 06:47 ET · Ratings

Evercore ISI Group Downgrades Cabaletta Bio to In-Line, Lowers Price Target to $6

BenzingaDec 20, 2024 06:37 ET · Ratings